Chengnuo Medicine

Cheng Nuo Medicine is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of novel small molecule therapeutics for cancer. The company focuses on the DNA damage response (DDR) and protein homeostasis pathways to create targeted therapies for patients with high unmet needs. Its lead program, CN001, is a potent and selective inhibitor of Ubiquitin-specific protease 1 (USP1), currently being evaluated in Phase 1 clinical trials for advanced solid tumors. The company's strategy involves leveraging synthetic lethality to treat cancers with specific genetic mutations, such as those in the BRCA pathway. Cheng Nuo Medicine was founded by industry veterans and is backed by prominent life science investors including 6 Dimensions Capital and Boyu Capital.